Implementation of Liquid Biopsies During Routine Clinical Care in Patients With Advanced Malignancies (LIQPLAT) - Trial NCT06367751
Access comprehensive clinical trial information for NCT06367751 through Pure Global AI's free database. This phase not specified trial is sponsored by University Hospital, Basel, Switzerland and is currently Not yet recruiting. The study focuses on Advanced Solid Tumor. Target enrollment is 150 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
University Hospital, Basel, Switzerland
Timeline & Enrollment
N/A
May 01, 2024
Oct 01, 2026
Primary Outcome
Number and proportion of patients in whom ctDNA was detectable before starting medical anticancer treatment,Patients in whom actionable alterations were identified in ctDNA analysis,Turn-around time of ctDNA analysis,ctDNA kinetics
Summary
The goal of this study is to assess the implementation and feasibility of ctDNA measurements
 from blood samples obtained during routine clinical care of cancer patients in the University
 Hospital Basel.
 
 Researchers will compare clinical and patient reported outcomes from the LIQPLAT study with
 patients who did not receive ctDNA measurements (external comparator from registry
 AO_2023-00091).
 
 Blood samples will be drawn from the patients as part of routine care and ctDNA measurements
 will be performed on these samples.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06367751
Non-Device Trial